Cannizzaro Hospital
Catania, 95126, Italy
NCT Number: NCT01223729
Minimal hepatic encephalopathy represents a common complication present in well-compensated cirrhotic patients that impairs patients daily functioning and health-related quality of life. Acetyl-L-carnitine has been shown to be useful in improving blood ammonia and cognitive functions in cirrhotic patients with minimal hepatic encephalopathy. This study evaluated the effects of acetyl-L-carnitine treatment on health related quality of life and on depression in patients with minimal hepatic encephalopathy.
Looking for future studies?
Notify Me34 year–67 year
All sexes
Interventional
Not applicable
Catania, 95126, Italy
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 g acetyl-L carnitine twice a day
placebo twice per day
University of Catania
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04058327
Acute-On-Chronic Liver Failure, Brain Diseases
Wuhan, Hubei, China
View Trial DetailsNCT03585257
Brain Diseases, Brain Diseases, Metabolic
Richmond, Virginia, United States
View Trial DetailsNCT04077125
Minimal Hepatic Encephalopathy
Roma, Italy
View Trial DetailsNCT02767622
Minimal Hepatic Encephalopathy
View Trial Details